Literature DB >> 9988341

Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G.

C L Chappell1, P C Okhuysen, C R Sterling, C Wang, W Jakubowski, H L Dupont.   

Abstract

A 50% infectious dose (ID50) of 132 Cryptosporidium parvum oocysts was previously determined in serologically negative individuals (ELISA). In this study, 17 healthy adults with pre-existing anti-C. parvum serum IgG were challenged with 500-50,000 oocysts. Infection and diarrhea were associated with the higher challenge doses. The ID50 was 1,880 oocysts, > 20-fold higher than in seronegative volunteers. Fecal oocysts were detected in only seven (53.8%) of 13 individuals with clinical cryptosporidiosis, indicating that the host response may effectively decrease the number of oocysts produced. Subjects with the highest absorbances prior to challenge had little to no increase in IgG following challenge, whereas volunteers with lower reactivities showed significant postchallenge increases. This suggests that an upper limit of serum IgG was present in some subjects, while others were further stimulated by an additional exposure. These data indicate that prior exposure to C. parvum provides protection from infection and illness at low oocyst doses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988341     DOI: 10.4269/ajtmh.1999.60.157

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  49 in total

1.  Serological responses to Cryptosporidium infection.

Authors:  T B Muller; F J Frost; G F Craun; R L Calderon
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Transforming growth factor beta1 is expressed in the jejunum after experimental Cryptosporidium parvum infection in humans.

Authors:  P Robinson; P C Okhuysen; C L Chappell; D E Lewis; I Shahab; S Lahoti; A C White
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Evaluation of ColorPAC Giardia/Cryptosporidium rapid assay and ProSpecT Giardia/Cryptosporidium microplate assay for detection of Giardia and Cryptosporidium in fecal specimens.

Authors:  M T Katanik; S K Schneider; J E Rosenblatt; G S Hall; G W Procop
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 4.  Cryptosporidiosis: environmental, therapeutic, and preventive challenges.

Authors:  S Collinet-Adler; H D Ward
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

5.  Evaluation of recombinant oocyst protein CP41 for detection of cryptosporidium-specific antibodies.

Authors:  Sonia A Kjos; Mark Jenkins; Pablo C Okhuysen; Cynthia L Chappell
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

6.  Serological responses to Cryptosporidium-specific antigens in Czech populations with different water sources.

Authors:  F Kozisek; G F Craun; L Cerovska; P Pumann; F Frost; T Muller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

7.  Cryptosporidium meleagridis: infectivity in healthy adult volunteers.

Authors:  Cynthia L Chappell; Pablo C Okhuysen; Rebecca C Langer-Curry; Donna E Akiyoshi; Giovanni Widmer; Saul Tzipori
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

8.  Serologic response to human Cryptosporidium infections.

Authors:  F J Frost; G F Caun
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

9.  Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion.

Authors:  James K Roche; Ana Lara Rojo; Lourrany B Costa; Ronald Smeltz; Patricio Manque; Ute Woehlbier; Luther Bartelt; James Galen; Gregory Buck; Richard L Guerrant
Journal:  Vaccine       Date:  2012-12-16       Impact factor: 3.641

Review 10.  Burden of disease from cryptosporidiosis.

Authors:  Debbie-Ann T Shirley; Shannon N Moonah; Karen L Kotloff
Journal:  Curr Opin Infect Dis       Date:  2012-10       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.